Bioventus (BVS)
(Delayed Data from NSDQ)
$11.85 USD
+0.26 (2.24%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.84 -0.01 (-0.08%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth F Momentum B VGM
Bioventus (BVS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$10.67 | $12.00 | $8.00 | -7.94% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Bioventus comes to $10.67. The forecasts range from a low of $8.00 to a high of $12.00. The average price target represents a decline of 7.94% from the last closing price of $11.59.
Analyst Price Targets (3 )
Broker Rating
Bioventus currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 2.33 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, two are Strong Buy, representing 66.67% of all recommendations. A month ago, Strong Buy represented 66.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.33 | 2.33 | 2.33 | 2.33 | 2.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
8/7/2024 | Craig-Hallum | Chase Knickerbocker | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.33 |
ABR (Last week) | 2.33 |
# of Recs in ABR | 3 |
Average Target Price | $10.67 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | 0.06 |
BVS FAQs
Bioventus Inc. (BVS) currently has an average brokerage recommendation (ABR) of 2.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 3 brokerage firms.
The average price target for Bioventus Inc. (BVS) is $10.67. The current on short-term price targets is based on 1 reports.
The forecasts for Bioventus Inc. (BVS) range from a low of $8 to a high of $12. The average price target represents a decline of $9.96 from the last closing price of $11.85.
The current DOWNSIDE for Bioventus Inc. (BVS) is 9.96%
Based on short-term price targets offered by three analysts, the average price target for Bioventus comes to $10.67. The forecasts range from a low of $8.00 to a high of $12.00. The average price target represents a decline of 7.94% from the last closing price of $11.59.